Hematologic Malignancy
Adult Hodgkin Lymphoma
CI-CAN-00001731Explore in graph →
Hematologic9 active trials
- NCIt
- C7702
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001731Explore in graph →
Clinical trials
123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (21)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04378647 | BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant(BRESELIBET) | unknown | Phase 2 | 150 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05137886 | PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | unknown | Phase 2 | 47 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER |
| 1 |
| Dec 17, 2021 |
| clinicaltrials |
| NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT01412307 | A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma(LEBEN) | unknown | Phase 1 / Phase 2 | 36 | Istituto Nazionale Tumori IRCCS - Fondazione G. PascaleNETWORK | 1 | Aug 11, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Feb 26, 2024source: clinicaltrials